Study of Livoletide (AZP-531) in PWS

Study Purpose

Millendo Therapeutics is preparing to initiate a Phase 2b/3 study for livoletide (AZP-531) with clinical sites in both the US and Europe.  Millendo recently acquired Alize Pharma and is continuing the development of livoletide in PWS.  Livoletide is an analogue of unacylated ghrelin, that counteracts some of the effects of acylated ghrelin, commonly referred to as the hunger hormone. Livoletide was previously studied in a double-blind, randomized, placebo-controlled Phase 2 clinical trial with a total of 47 subjects with PWS, demonstrating an improvement in hyperphagia as measured by the HQ at 2 weeks.  (https://www.ncbi.nlm.nih.gov/pubmed/25989955)

Recruitment Criteria

Study Type: not yet recruiting
Eligible Ages: 12 - 65 years
Other Criteria: BMI < 65 kg/m2

Trial Details

Trial Id: not yet recruiting
Phase: 2b/3
Duration: TBD
Status:
 not yet recruiting
Lead Sponsor: Millendo
Countries: United States
Additional Details: 

Eligibility Criteria

More information on Millendo and livoletide can be obtained at www.millendo.com. Trial details will be available later in 2018.

Tools for PWS Awareness

Volunteer Your Time

No matter how big or how small, every effort helps us!

VOLUNTEER